Erica L. Goodrich

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

Ofri Mosenzon, Stephen D. Wiviott, Avivit Cahn et al. · The Lancet Diabetes & Endocrinology · 2019 · 675 citations · Full text

Medicine, Nephrology, Pharmacology +14

Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease

Marc P. Bonaca, Deepak L. Bhatt, Robert F. Storey et al. · Journal of the American College of Cardiology · 2016 · 387 citations

Medicine, Cardiology, Pharmacotherapy +15

Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk

Brian A. Bergmark, Nicholas Marston, Thomas A Prohaska et al. · New England Journal of Medicine · 2024 · 182 citations

Pharmacy, Pharmacology, Pharmacotherapy +14

Interleukin‐6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID‐TIMI 52 (Stabilization of Plaque Using Darapladib—Thrombolysis in Myocardial Infarction 52) Trial

Christina Fanola, David A. Morrow, Christopher P. Cannon et al. · Journal of the American Heart Association · 2017 · 153 citations · Full text

Medicine, Cardiology, Immunology +17

Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study

Avivit Cahn, Ofri Mosenzon, Aliza Rozenberg et al. · Diabetes Care · 2019 · 131 citations

Pharmacy, Pharmacology, Pharmacotherapy +15